AUTHORS
Victor Zibara, MD, Sruti Shiva, PhD2, Anuj Raj Kaul3, Troy Holden, MD4, Craig Seaman, MD5, Frederico Xavier, MD, MS6, Nicoletta C Machin, DO, MS7
AFFILIATIONS
1 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
4 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
7 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
ABSTRACT
Background and Significance:
Iron deficiency is highly prevalent among individuals with inherited bleeding disorders (IBDs) because of chronic blood loss and recurrent bleeding. Although iron deficiency is traditionally recognized for its contribution to anemia, emerging evidence suggests that it may also impair platelet function and contribute to bleeding severity independent of hemoglobin concentration. Experimental and clinical studies have demonstrated abnormalities in platelet activation, aggregation, and adhesion during iron deficiency that improve following iron repletion. However, the clinical significance of these findings in patients with inherited bleeding disorders remains unknown. Prospective studies have not systematically evaluated whether correction of iron deficiency improves bleeding phenotype or explored the mechanisms underlying these observations. The IRON-BD study was designed to address this important knowledge gap by evaluating changes in bleeding symptoms, quality of life, and platelet function following intravenous iron replacement in iron-deficient patients with inherited bleeding disorders.
Study Design and Methods:
IRON-BD (NCT07083583) is a prospective, single-center observational cohort study conducted at the Hemophilia Center of Western Pennsylvania. Forty participants aged ≥15 years with an inherited bleeding disorder—including von Willebrand disease, an inherited platelet disorder, a coagulation factor deficiency, or bleeding disorder of unknown cause—and laboratory-confirmed iron deficiency, defined as a serum ferritin level <50 ng/mL, will be enrolled over a two-year recruitment period. Participants receive intravenous iron replacement as part of standard clinical care, independently of study participation; no investigational therapeutic intervention is administered.
Baseline assessments performed before intravenous iron administration include validated bleeding assessments using the ISTH Self-Bleeding Assessment Tool (Self-BAT) and Pictorial Bleeding Assessment Chart (PBAC); quality-of-life assessments using the 36-Item Short Form Health Survey (SF-36) and FACIT Fatigue Scale; complete blood count; iron studies; bleeding disorder–specific laboratory testing; and comprehensive platelet function analyses. Platelet studies include measurement of surface P-selectin expression, activated glycoprotein IIb/IIIa expression, responses to ex vivo stimulation with ADP and thrombin, and reactive oxygen species generation. Clinical, laboratory, bleeding, and quality-of-life assessments are repeated three months after iron replacement.
The primary endpoint is the change in ISTH Self-Bleeding Assessment Tool (Self-BAT) score from baseline to three months following intravenous iron replacement. Secondary endpoints include changes in Pictorial Bleeding Assessment Chart (PBAC) scores among participants who menstruate, quality-of-life measures assessed using the SF-36 and FACIT Fatigue Scale, iron parameters, hematologic indices, and platelet function assays. These mechanistic analyses are intended to investigate the biological pathways through which iron deficiency may influence hemostasis and bleeding symptoms.
Conclusion:
IRON-BD is among the first prospective studies specifically designed to investigate whether iron deficiency is a modifiable contributor to bleeding severity in patients with inherited bleeding disorders. By integrating validated clinical bleeding assessments with detailed platelet function analyses before and after iron repletion, this study seeks to clarify the relationship between iron deficiency and hemostatic dysfunction. If iron repletion is associated with improvements in bleeding symptoms and platelet function, the findings could support earlier identification and treatment of iron deficiency as an adjunctive strategy to optimize bleeding management beyond conventional hemostatic therapies.
DISCLOSURES
Victor Zibara, MD: No relevant conflicts of interest to declare.